Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 1384-1397 | ISSN:2251-6727

Artificial Intelligence: Deciphering the Promising New Way to Detect Early Signs of Lung Cancer

Sandhya Borse[1*], Shweta Shahare[2], Dhanashree Mali[3], Aditya Medhe[4], Rushikesh Shinde[4], Prathamesh Ware[4],

[1*]Associate Professor, Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra 422213, India

[2]Associate Professor, Department of Pharmaceutics, R G Sapkal Institute of Pharmacy, Nashik, Maharashtra 422213, India

[3]Assistant Professor, Department of Pharmaceutical Chemistry, GES's Sir Dr. M. S. Gosavi College of Pharm. Edu. And Research, Nashik, Maharashtra 422005, India

[4]Department of Quality Assurance, School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra 422213, India

***Address for correspondence**

Dr. Sandhya L. Borse, Associate Professor, Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra 422213.

(Received: 16 July 2025 Revised: 20 August 2025 Accepted: 20 September 2025)

KEYWORDS

Artificial intelligence, Lung cancer, Sybil

ABSTRACT:

Artificial intelligence (AI) is transforming lung cancer diagnosis by combining computed tomography imaging technology with AI apps. However, images like chest X-rays and CT scans may miss small tumors or those still in their early stages, leading to false positives and unnecessary tests. AI can improve early detection by making it easier to get tests, finding biomarkers, lowering diagnostic errors, personalizing screening, integrating data, making healthcare more accessible, and constantly changing. AI's ability to find biomarkers and merge multimodal data, including imaging, pathology, and electronic health records, allows for more accurate diagnostic tests and better treatment choices. AI has become a crucial field in clinical areas, particularly in imaging analysis, histopathology evaluation, and genomic assessment of lung cancers. AI is transforming research on lung cancer and therapy, particularly in the identification of promising biomarkers. AI systems have proven their capacity to improve diagnostic precision by minimizing the likelihood of erroneous outcomes, enabling radiologists to make better choices and reduce the incidence of diagnostic errors. AI technologies are crucial for the precise interpretation of genomic markers critical for early detection, accurate diagnosis, and personalized therapy options. Healthcare professionals can employ AI algorithms to develop personalized treatment regimens that correspond with a patient's distinct genetic profile, ensuring medications target the molecular characteristics of their malignancy.

Introduction:

A. Challenges in Lung Cancer Detection

Among the most prevalent cancers worldwide is still lung cancer, killing a huge number of people every year. Even though there is a new screening suggestion that was meant to help find problems earlier, very few people are actually getting these potentially life-saving screenings. Less than 6% of those who are eligible have had the recommended screenings. There is new hope, though, that lung cancer can be found more quickly thanks to improvements in combining computed tomography imaging technology with artificial intelligence apps.

In its early stages, lung cancer often doesn't show any signs. People may not know what their symptoms are or think they are signs of something else, like a persistent cough, shortness of breath, or chest pain. Chest X-rays and CT scans are helpful, but they might miss small tumors or ones that are still in the early stages. Also, sometimes they give false positives, which causes stress and more tests that aren't needed. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two forms of lung cancer, each with its own subtypes. On imaging, each group may look different, and it may be necessary to use different methods to diagnose each one. Biomarkers are chemicals in the blood that show if someone has cancer. Their use is still changing. Some biomarkers can help with detection and treatment, but not all of them can be used everywhere, and their sensitivity and specificity can vary. Some screening tests, like low-dose CT scans, can give false positives or false negatives. This makes detection more difficult and can cause needless procedures or missed diagnoses.

The progress made in AI gives us hope in the fight against lung cancer. AI has ability to alter the way lung cancer is diagnosed by making it easier to get tests, finding biomarkers, improving early diagnosis, lowering diagnostic errors, personalizing screening, integrating data, making it easier for people to get to, and always changing. As these technologies are improved and used more, priority should be given to finding lung cancer more accurate, faster, and easier for everyone. This will eventually produce better patient results and progress in the field of oncology.

B. How Artificial Intelligence Can Help Find Lung Cancer

The use of AI is revolutionizing the way lung cancer is found and has the ability to solve many problems. AI is changing how lung cancer is diagnosed by-

Improving Early Detection[1, 2]: Taking advantage of AI's promise, better imaging stands out as an area that could be changed. Modern computer programs can read CT scans and X-rays more accurately than a trained human eye can often. At this level of accuracy, it's usually easy to find a number of small, hidden tumors that even the best doctor might miss in their early stages. Also, AI is very good at finding structures and patterns in pictures that are very complicated and might not be visible to the naked eye. This makes it more likely that problems will be found early on.[3]

Eliminating false positives and negative results: Artificial intelligence has come a long way, especially in eliminating false positives and negative results. The specificity of nodule classification in AI systems could be improved by using the right algorithms that have been trained on big datasets. This would make it easier to tell the difference between benign and malignant nodules. This not only keeps patients from having to deal with unnecessary worry and invasive therapy, but it also makes sure that those who do have real concerns are taken care of quickly. Having AI that can control risks in this way is important because it lets doctors test only the people who are most likely to need more extensive tests.[4, 5, and 6]

Personalized Screening: The areas of personalization have a lot to do with the building of computer-based technologies. But it's when information about each patient is taken into account, like whether they smoke or if they have certain genetic traits, that AI changes screening methods to fit each patient's unique risk factors. This personalized screening method makes these kinds of programs more effective and leads to better results. AI's suggestive models change over time as more data is added. This is done so that screening standards can be better suited to new trends and each patient's unique traits.[7,8]

Biomarker Identification: AI's ability to find biomarkers is a key part of making diagnosis tools better. AI can sort through massive quantities of genomic database and help find new findings linked to lung cancer. This may result in the creation of more accurate diagnostic tests. Artificial intelligence (AI) makes blood sample studies more sensitive and specific, which means they can find cancer biomarkers more reliably and with less damage.[9]

Integrating Multimodal Data: AI's merging of multimodal data, which includes imaging, pathology, and electronic health records (EHRs), gives a full picture of a patient's health. This in-depth study makes it easier to create models that can predict when cancer will start or get worse, so treatment choices can be made earlier and with more information.[10]

Making it easier for people to get medical care: AI has made a big difference in telemedicine and remote analysis, especially in areas that don't get enough medical care or advanced diagnosis tools. AI is a key part of making healthcare more accessible because it makes it easier to look at images and patient data from afar. AI also automates routine diagnostic tasks, which saves healthcare workers valuable time that they can use to concentrate more difficult cases and give better therapy for patients.[11]

Continuous Learning and Improvement: One significant way that AI is better at finding lung cancer is by constantly learning and adapting. This is called "iterative nature." AI systems that change over time based on new data and results can get better over time, adapting to new problems and incorporating the newest study and best clinical practices.[12]

C. Advancing Lung Cancer Detection with AI

AI has successfully been applied in various clinical areas, including disease detection, diagnosis, and risk stratification for developing diseases. As a result, it is now recognized as a crucial field for AI, particularly in imaging analysis, histopathology evaluation, and genomic assessment of lung cancers.[13]

It operates using Optellum AI software, which has been trained on extensive datasets of CT scans and diagnoses sourced from healthcare systems in the UK, the USA, and across Europe.[14] This technology distinguishes between lung nodules that are benign and cancerous and provides a prediction score—ranging from 1 to 10—for lung cancer for each sampled nodule. The scoring process is rapid, allowing attending clinicians to receive a tailored risk assessment that aids in early diagnosis and treatment.[15]

Sybil is an AI model created by a research team at Abdul Latif Jameel's MIT Machine Learning in Health Clinic, in partnership with Massachusetts General Cancer Center and Chang Gung Memorial Hospital. By utilizing deep learning, this model can assess the risk for lung cancer according to a patient's LDCT results, enabling earlier detection and improving treatment outcomes. Sybil is a variation of the name Sibyls, referring to ancient Greek oracles believed to possess divine insight and the ability to predict the future.[11] Similarly, the AI model can project future risks over a six-year period using LDCT scans independently, without needing a radiologist's help for risk identification. The most common cause of cancer-related mortality is still lung cancer globally, with 1.7 million fatalities reported in 2020 alone. One significant element that contributes to the lethality of lung cancer is its tendency to present clinically at a very late stage, by which time treatment options have become limited and less effective. For lung cancer to have a 5-year survival rate, early identification is essential. It is estimated that the five-year survival rate for patients diagnosed early is around 70%, while for those diagnosed at later stages, it drops to below 10%. An investigation that appeared in the Journal of Clinical Oncology proved the effectiveness of the model across various datasets. For instance, the C-indices for Sybil on the NLST, MGH, and CGMH datasets were 0.75, 0.81, and 0.80, respectively. These figures indicate a good to strong predictive performance. Additionally, all of its one-year prediction ROC-AUC scores ranged from 0.86 to 0.94, highlighting the model's accuracy. Building Sybil was quite challenging because lung CT scans are three-dimensional, and in the early stages, lung cancer is relatively small compared to the overall size of the lung. The imaging data used to train Sybil often lacked clear evidence of most cancer cases. However, if the model had been trained on labelled CT scans that showed cancerous tumors, it could have better predicted the risk of cancer. It was surprising to find that Sybil could identify individuals at risk of cancer even when they showed no symptoms.[16,17]

D. Employing AI for enhanced accuracy in lung cancer detection

AI has been useful successfully in many clinical sectors, such as finding illnesses, diagnosing them, and figuring out who is most likely to get them. Artificial intelligence is now seen as very important in this area, especially for looking at lung cancer through imaging, histology, and genomics.[13] This method works with Optellum AI software that has been trained on huge amounts of CT scans and diagnoses from healthcare systems in the UK, the USA, and all over Europe.[14] For each sampled nodule, this technology tells the difference between cancerous and noncancerous nodules in the lungs and gives a prediction score for lung cancer running from 1 to 10. Rapid scoring lets attending clinicians get a personalized risk estimate that helps with early diagnosis and treatment.[15] Scientists at Abdul Latif Jameel's MIT Machine Learning in Health Clinic, working with the Massachusetts made the AI model Sybil. Utilizing deep learning, this model can figure out the risk based on their LDCT results. This allows for earlier diagnosis and better treatment outcomes. A variation on the name Sibyls, which comes from the name of old Greek oracles who were thought to have divine knowledge and could see into the future. Additionally, the AI model can predict future risks over a period of six years using LDCT scans without the help of a doctor. Lung cancer is very deadly as globally 1.7 million people died in 2020, because it usually shows up as symptoms very late in the disease's development, when there are few options for treatment and less likely to work. A higher five-year mortality rate for lung cancer depends on finding it early. The chance of survival after five years is about 70% for people who are found early and below 10% for people who are diagnosed later. An article in the J. Clin. Oncol verified that the model worked well with different types of data. For example, Sybil's C-indices on the NLST sample were 0.75, 0.81, and 0.80, respectively. According to these numbers, the ability to guess is good to strong. Moreover, all of its ROC-AUC scores predictions were between 0.86 and 0.94, which suggests that the model was very accurate. There were a lot of challenges in making Sybil because lung CT pictures are three-dimensional and lung cancer is usually pretty small compared to the lung itself when it is first found. Much of the time, the imaging data that Sybil was trained on didn't show clear proof of most cancer cases. In contrast, the model would have been better at predicting the risk of cancer if it had been taught on labeled CT scans that showed tumors that were cancerous.[16,17] Social stigma, disparate regulations, and eligibility criteria that have traditionally emphasized smokers could be a factor in low detection rates for lung cancer throughout much of the United States. It's essential to acknowledge that the most patients currently diagnosed are either non-smokers or former smokers. The Taiwanese dataset suggests that Sybil has potential for generalization to never-smokers. Subsequent research should assess Sybil in a more diverse group, encompassing both non-smokers and persons who ceased smoking long ago.[18] Lung cancer, primarily attributable to cigarette smoking, is the main reason why people die from cancer in the US.. Although helical CT screening effectively reduces mortality, it is related with a significant incidence of false positives. The National Lung Screening Trial demonstrated that low-dose CT-screening decreased mortality from lung cancer by 20% relative to routine chest X-rays, however it also exhibited a false-positive rate of approximately 23%.[19] Researchers are employing AI to enhance the precision of lung cancer screening. Artificial intelligence, particularly deep learning, can reduce false-positive rates and enhance diagnostic precision. The National Cancer Institute (NCI) is supporting the creation of AI systems to assist radiologists in interpreting CT scans.[20] A five-year agreement with Booz Allen Hamilton is dedicated to the collection and storage of CT scans and clinical data for artificial intelligence research. The integration of AI techniques with biomarkers may enhance the early diagnosis.[21]

1. Technology for Blood Tests

Using artificial intelligence, researchers at the Hopkins Cancer Center have made a new type of blood test named DELFI (DNA Evaluation of Fragments for Early Interception). This test can find more than 90% of lung cancers because it can spot certain patterns in the DNA pieces that cancer cells release. By looking at how DNA is broken up in the bloodstream, it can tell the difference between cancerous and healthy patterns.[21]. A study with almost 800 people from the U.S., the Netherlands, and Denmark found that DELFI was very accurate, finding 94% of lung cancer cases in all stages and types. This includes 96% of cancers in their later stages and 91% of cancers in their early stages. These results, which were published in Nature Communications, show that DELFI has the ability to make lung cancer screening better. This is especially important because current methods like low-dose CT scans don't work very well and give a lot of false positives. The test is affordable and easy to use, which makes it a good choice for general cancer screening.[22.] Cancer that kills the most people in the U.S. and around the world is lung cancer. Computed tomography (CT) screenings once a year can help find lung cancer early in high-risk individuals, but only 6 to 10 percent of those who are qualified actually go through with them. An artificial intelligence (AI) liquid biopsy was created and tested by researchers at Johns Hopkins Medicine. It uses specific patterns of DNA pieces found in blood samples to find lung cancer earlier.[23]. The new test, which was released in Cancer Discov on June 3, 2024, is meant to make detection better and lower rate of death. Around 1,000 people from 47 sites in 23 U.S. states took part in the study. Investigators at Hopkins Cancer Center created AI system instrument intended to identify lung early detection of cancer with a standard blood test. This test analyzes DNA fragment patterns in the blood to detect lung cancer, perhaps resulting in increased screening rates and reduced mortality rates.[24,25] Currently, about 6-10% of eligible adults between 50 to 80 age with a history of cigarette smoking get lung cancer screening, mostly due to the time and radiation exposure linked to CT scans. The AI test, verified in a research with 382 people, demonstrates a negative predictive value of 99.78%, suggesting that merely 2 out of every 1,000 cases would be missed. Computer simulations suggest that elevating screening rates to 50% may quadruple lung cancer detection and improve early detection by 10%, potentially preserving 14,000 lives over five years. The test is cost-efficient and may be conducted in a physician's office, enhancing the accessibility of lung cancer screening.[26, 27] Researchers from the Hopkins Cancer Center and other universities recently introduced an AI-driven liquid biopsy blood test that analyzes genetic markers in the circulation to identify patients at risk

for lung cancer. This innovation could enhance screening rates and markedly decrease lung cancer mortality, which is presently the foremost source of cancer-related fatalities globally, according to the World Health Organization.

Researchers at Washington University have developed a machine learning system capable of precisely predicting the beginning of brain metastases in early-stage non-small cell lung cancer patients. This article, published on March 4, 2024, in The Journal of Pathology, emphasizes the capacity of AI to revolutionize cancer treatment by detecting individuals predisposed to brain metastases.[28] Lung cancer continues to be the primary cause of cancer-related fatalities. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery is generally the primary choice when the tumor is localized to the lung. Approximately 30% of these patients may move on to more advanced phases of cancer, requiring more intensive therapies like chemotherapy, radiation therapy, and immunotherapy. At present, there are no dependable instruments for physicians to forecast which patients may develop brain metastases, resulting in both over-treatment and under-treatment.[29] A study team headed by Dr. Richard J. Cote, alongside Dr. Ramaswamy Govindan, Dr. Mark Watson, and Dr. Changhuei Yang, developed an AI software utilizing 118 lung biopsy specimens. The accuracy of the algorithms was assessed on 40 samples. The findings revealed that the AI attained an accuracy rate of 87% in forecasting brain metastasis, surpassing pathologists, who generally exhibited an accuracy of 57.3%. This signifies a notable progression in AI utilization, perhaps resulting in a tool that can assist in strategizing cancer therapy and function as an efficacious therapeutic alternative for patients. Although additional validation is required for the study, experts are hopeful about potential of AI to improve patient care and reduce superfluous treatments.[27]

2. Artificial Intelligence-Enhanced Liquid Biopsy Assay

Annually, around 1.8 million deaths occur due to lung cancer, rendering it the major cause of death from cancer worldwide. Researchers at the JHK Cancer Center, in collaboration with other institutions in U.S., have successfully performed liquid biopsy utilizing blood samples from patients with an aggressive form of lung cancer. This groundbreaking blood test, described in a study published on August 28, 2019, in Cancer Discovery, seeks to improve lung cancer screening and enable earlier disease identification. In the last five years, researchers have created a test to detect DNA fragment patterns in lung cancer patients. Participants were chosen based on their eligibility for LDCT screening, encompassing individuals with and without cancer. The scientists trained the AI software on blood samples from 576 individuals and subsequently verified it with a separate cohort of 382 individuals. The test attained an exceptional negative predictive value of 99.8%, signifying that the probability of overlooking a case was merely two out of every 1,000 tested. The researchers seek to secure FDA approval and broaden the test to detect additional cancer types.[30, 31] Victor Velculescu, a professor at Johns Hopkins and codirector of the Cancer Genetic and Epigenetic Program, characterized it as economically viable on a big scale, hence enhancing the accessibility of lung cancer screening to a wider demographic. This accessibility is essential, as early detection is pivotal in the effective treatment of many tumors. A recent study by experts at the JHK Cancer Center has launched a liquid biopsy called DELFI, which employs artificial intelligence (AI) to detect lung cancer considerably sooner than conventional procedures.[32] Published in Cancer Discovery on June 3, the study illustrated that the AI could forecast lung cancer by analyzing DNA fragment patterns seen in blood samples. This observational study included 969 patients at elevated risk for lung cancer, conducted across 47 locations in 23 U.S.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1384-1397 | ISSN:2251-6727

states, with outcomes assessed prospectively. The AI program was trained on 576 blood samples and subsequently validated on a second cohort of 382 individuals. The test exhibits an exceptional negative predictive value of 99.78%, failing to identify only 2 out of every 1,000 cases. Computer simulations suggest that if 50% of individuals classified as high-risk were to get this test within five years, detection rates might increase fourfold, and early diagnosis may enhance by 10%, thereby preserving the lives of at least 14,000 individuals. The test is economically efficient and scalable, with all procedures patented by DELFI Diagnostic. The team, whose research has been published in the journal Nature Genetics, aims to progress their breakthrough discovery into clinical trials shortly. This would enable presentation to health regulators for clearance by entities like the Food and Drug Administration (FDA), perhaps helping numerous other cancer assays as well.[33]

3. Artificial Intelligence Improving the Detection of Potential Biomarkers for Lung Cancer

AI is profoundly transforming the domain of lung cancer research and therapy, particularly in the identification of promising biomarkers. These biomarkers are crucial for early identification, precise diagnosis, and customized treatment strategies. Artificial intelligence enhances the discovery process through the rigorous analysis of extensive medical and genomic datasets.[34]

3.1 Artificial Intelligence in Imaging Analysis

AI is revolutionizing medical imaging, significantly enhancing the identification and lung cancer detection. This review analyzes the enhancement of probable lung cancer marker identification using image analysis through AI. We examine several AI methodologies, their impact on diagnostic precision, and the ramifications for customized medicine.

Algorithms for Deep Learning

Convolutional Neural Networks (CNNs) are at the forefront of artificial intelligence in images processing. These algorithms proficiently analyze chest CT scans and X-rays, adeptly discerning complex patterns indicative of lung cancer. Through the utilization of comprehensive, annotated datasets, CNNs can precisely detect and categorize lung nodules, tumors, and other anomalies. The integration of CNNs into clinical practice has improved the detection process, reducing the likelihood of missed diagnoses and augmenting overall diagnostic efficacy. The detection and segmentation skills of AI have considerably enhanced the precision of imaging analysis. Automated techniques can accurately identify and segment nodules, facilitating a more focused analysis of worrisome regions. This segmentation assists radiologists in identifying probable malignant areas, minimizes human error, and alleviates the burden of manual analysis.[1]

Radiomics

Radiomics-based feature extraction emphasizes the analysis of quantitative image characteristics such as texture, shape, and intensity. AI algorithms excel at analyzing these features, revealing trends that may suggest malignancy. Texture analysis helps differentiate between benign and malignant tumors, providing critical information regarding tumor behavior and features. Predictive modeling employing radiomic characteristics facilitates the development of models intended to evaluate malignancy likelihood and anticipate tumor progression. These models are essential for risk classification, aiding in the prioritization of patients for further inquiry via quantitative analysis of imaging data.[35]

Risk Stratification and Diagnostic Precision

Artificial Intelligence enhances Risk Assessment Models by integrating imaging data with patient demographics and clinical history. This comprehensive method improves risk stratification, allowing for more accurate identification of patients requiring additional testing or action. The capacity to predict cancer risk by imaging features facilitates more effective and prompt care of lung cancer. AI systems have proven their capacity to improve diagnostic precision by minimizing the likelihood of erroneous outcomes. These tools provide additional analytical layers, highlighting potential issues that could otherwise be overlooked. This support helps radiologists make better decisions and lowers the frequency of diagnostic errors.[36]

Enhancement of Workflow Efficiency

The utilization of AI techniques for automated analysis improves common tasks such as image pre-processing and lesion detection. This automation alleviates strain of radiologists so they can concentrate on more difficult diagnostic problems. The efficiency attained by AI-driven analysis results in expedited patient processing and reduced waiting times for diagnostic outcomes. AI-powered decision support tools provide evidence-based guidance and identify areas necessitating additional scrutiny. These tools enhance workflow by providing radiologists with actionable insights and streamlining the diagnostic process. AI in Clinical Practice facilitates a more efficient and effective approach to identifying lung cancer.[37]

Personalized Medicine

Artificial intelligence is essential in customizing treatments by analyzing intricate imaging data to guide therapeutic decisions. By identifying distinct tumor characteristics via AI-augmented imaging, healthcare professionals can customize treatment strategies, potentially incorporating targeted medications and surgical interventions. This personalized approach improves treatment outcomes and aligns with the objectives of precision medicine. Assessing treatment efficacy is another domain in which AI exhibits its utility. AI systems can assess the efficacy of patient treatment by analyzing temporal variations in imaging data. This capability facilitates real-time adjustments to treatment regimens, guaranteeing that interventions remain optimal and effective along the care continuum.[38]

Incorporation of Emerging Technologies

The integration of modalities is an emerging approach wherein AI amalgamates data from many imaging techniques, *including CT, PET, and MRI, for detailed evaluation. This multimode*l *evaluation* enhances the identification and characterisation of lung cancer, offering a more comprehensive picture of the illness. Artificial intelligence in 3D imaging markedly improves the spatial localization and assessment of malignancies. Utilizing modern analytical methodologies facilitates enhanced planning for surgery and radiation therapies, resulting in superior treatment plans. Artificial intelligence is revolutionizing image analysis in lung cancer by enhancing the discovery and characterization of possible biomarkers. AI solutions enhance diagnostic precision and optimize workflows through the *use* of advanced deep learning algorithms, the extraction of radiomic characteristics, and the use of predictive modeling. The *use* of AI in clinical practice is improving personalized medicine by facilitating tailored treatments and real-time *management* of disease development. With the progression of AI technologies, their impact on lung cancer diagnosis and treatment is predicted to *grow*, resulting in more effective and precise patient care.[39.40]

3.2 Artificial Intelligence in Genomic Data Analysis

AI is revolutionizing various fields of medicine, especially oncology, by enhancing the processing of genetic data. AI technologies are crucial for the accurate determination and interpretation of genomic markers critical for early detection, accurate diagnosis, and personalized therapy options. This paper analyzes how AI is transforming genetic data analysis to identify probable lung cancer markers, highlighting recent developments, practical applications, and their effects on patient treatment.[41]

Genomic Pattern Recognition

Artificial intelligence excels in identifying patterns within genomic data. Machine-learning techniques, especially deep-learning models, are engineered to reveal complex patterns and relationships within large genomic datasets. These patterns can elucidate mutations and genetic alterations associated with lung cancer. AI algorithms can analyze sequencing data to detect recognized mutations in genes such as EGFR that is epidermal growth factor receptor, which are crucial for understanding cancer biology and guiding therapy decisions. AI-driven mutational analysis facilitates the accurate and efficient detection of particular genetic alterations linked to lung cancer. Patient genetic data after analysis with extensive reference databases, AI can be used to identify actionable mutations and predict their possible impacts on disease development and treatment results. [42]

Predictive Modeling

AI-driven predictive models integrate genetic data with clinical database to forecast illness outcomes and therapy responses. These models utilize algorithms to analyze patterns in genomic alterations and associate them with outcome data for patients, including survival rates and consequences to particular treatments. AI-based models can assess the likelihood of a patient benefiting from tailored medicines by assessing their unique genomic profile. AI-generated risk assessment instruments can classify patients based on their genetic risk factors. Through the analysis of genomic data alongside environmental and clinical information, AI provides a comprehensive risk assessment, allowing doctors in order to determine who is more likely to get lung cancer and implement preventative actions appropriately.[43.44]

Integration of Multi-Omics Data

Multi-Omics Integration denotes the amalgamation of genomic data with diverse omics data types, encompassing transcriptomic, proteomic, and metabolomic information. AI systems proficiently integrate various data kinds, providing comprehensive insights into lung cancer biology. This holistic approach facilitates the identification of novel biomarkers and pathways that may remain obscured when analyzing genomic data in isolation. AI-augmented multi-omics analysis for thorough biomarker identification can reveal novel potential markers for lung cancer. Through the integration of data from various sources, AI may discern complex relationships and regulatory networks involved in tumor genesis and progression.[45.46]

Precision Medicine and Tailored Therapeutics

The analysis of genomic data by AI significantly enhances tailored treatment strategies. Healthcare professionals can employ AI algorithms to develop personalized treatment regimens that correspond with a patient's distinct genetic profile, ensuring medications target the molecular characteristics of their malignancy. AI can identify suitable candidates for therapies targeting specific genetic mutations, such as EGFR inhibitors for individuals with EGFR mutations. Supervising and modifying treatment in accordance with genetic data is a crucial domain where AI is exerting a substantial influence. AI systems can monitor alterations in a patient's genetic profile over time to assess therapy efficacy and implement real-time adjustments. This adaptable method of therapy management improves

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1384-1397 | ISSN:2251-6727

patient outcomes by aligning therapeutic tactics with the evolving genetic traits of the tumor.[47, 48]

Obstacles and Prospective Pathways:

The promise of AI in the Lung cancer genetic data analysis is substantial, although numerous hurdles must be confronted. The uniformity and quality of data are essential for the effective implementation of AI modalities. Ensuring the precision and consistency of genomic data is important for evaluating credible outlooks and recommendations with AI. Comprehending AI models constitutes an additional hurdle. While AI algorithms can provide significant insights, it is essential to understand the mechanisms by which these models reach their results for their acceptance in clinical environments and impact on decision-making. Present investigations concentrate on enhancing the transparency and interpretability of AI-driven genomic analysis.

Ethical and privacy problems are paramount as AI technologies in genomics progress. Safeguarding patient data and guaranteeing its ethical utilization are crucial for preserving trust and complying with regulatory requirements. AI is markedly enhancing the diagnosis of potential biomarkers for lung cancer through the analysis of genomic data. AI is improving early detection, tailored treatment, and overall patient care through the application of advanced algorithms for pattern recognition, predictive modeling, and multi-omics integration. As AI technologies advance, their integration into genetic analysis is anticipated to yield progressively precise and efficient methods for lung cancer management. Addressing current obstacles and highlighting future developments will be crucial for maximizing the benefits of AI in the critical domain of oncology.

Conflict of interest

The authors of the manuscript entitled "Artificial Intelligence: A Promosing New Way to Detect Early Signs of Lung Cancer" declare that they have no potential conflict of interest regarding submission and publication of this manuscript.

Acknowledgement

The authors wish to acknowledge School of Pharmaceutical Sciences, Sandip University, Nashik for their support and cooperation.

References:

1. Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L. & Corrado, G. S. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25(6), 954-961. https://doi.org/10.1038/s41591-019-0447-x
2. Hunter B, Hindocha S, Lee RW. The Role of Artificial Intelligence in Early Cancer Diagnosis. Cancers (Basel). 2022 Mar 16;14(6):1524. doi: 10.3390/cancers14061524. PMID: 35326674; PMCID: PMC8946688.
3. Thanoon MA, Zulkifley MA, Mohd Zainuri MAA, Abdani SR. A Review of Deep Learning Techniques for Lung Cancer Screening and Diagnosis Based on CT Images. Diagnostics (Basel). 2023 Aug 8;13(16):2617. doi: 10.3390/diagnostics13162617. PMID: 37627876; PMCID: PMC10453592.
4. McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., ... & Suleyman, M. (2020). International evaluation of an AI system for breast cancer screening. Nature, 577(7788), 89-94. https://doi.org/10.1038/s41586-019-1799-6
5. Chassagnon, Guillaume & Vakalopoulou, Maria & Paragios, Nikos & Revel, marie-pierre. (2019). Artificial Intelligence Applications for Thoracic imaging. European Journal of Radiology. 123. 108774. 10.1016/j.ejrad.2019.108774.

6. Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A. & Mak, R. H. (2019). Artificial intelligence in cancer imaging: clinical challenges and applications. CA: A Cancer Journal for Clinicians, 69(2), 127-157. https://doi.org/10.3322/caac.21552

7. Oudkerk, M., Liu, S., Heuvelmans, M. A., Walter, J. E., & Field, J. K. (2021). Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. Nature Reviews Clinical Oncology,

18(3), 135-151. https://doi.org/10.1038/s41571-020-00432-6

8. National Lung Screening Trial Research Team. (2019). Outcomes of individualized lung cancer screening based on predictive modeling. The Lancet Oncology, 20(12), 1676-1685. https://doi.org/10.1016/S1470-2045(19)30477-4

9. Casagrande, Giovanna Maria Stanfoca, Marcela de Oliveira Silva, Rui Manuel Reis, and Letícia Ferro Leal. 2023. "Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs" International Journal of Molecular Sciences 24, no. 3: 2505. https://doi.org/10.3390/ijms24032505

10. Liu, Y., Chen, P. H. C., Krause, J., & Peng, L. (2019). How to read articles that use machine learning: Users' guides to the medical literature. JAMA, 322(18), 1806-1816. https://doi.org/10.1001/jama.2019.16489

11. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., ... & Dean, J. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24-29. https://doi.org/10.1038/s41591-018-0316-z

12. Erickson, B. J., Korfiatis, P., Akkus, Z., Kline, T. L. (2017). Machine learning for medical imaging. Radiographics, 37(2), 505-515. https://doi.org/10.1148/rg.2017160130

13. Lung Cancer Research Foundation. "The Role of Advanced Imaging in Lung Cancer Detection." Accessed Jan 23, 2024.

14. Optellum. (2022). Optellum AI platform for lung cancer. Optellum Website. https://optellum.com/

15. Liu, Y., Gadepalli, K., Norouzi, M., Dahl, G. E., Kohlberger, T., Boyko, A., ... & Corrado, G. S. (2017). Detecting cancer metastases on gigapixel pathology images. arXiv preprint arXiv:1703.02442. https://doi.org/10.1038/nature21056

16. National Cancer Institute. (2021). National Lung Screening Trial (NLST). National Cancer Institute (NCI). https://www.cancer.gov/types/lung/research/nlst

17. Mikhael, P. G., Wohlwend, J., Yala, A., Karstens, L., Xiang, J., Takigami, A. K., Bourgouin, P. P., Chan, P., Mrah, S., Amayri, W., Juan, Y. H., Yang, C. T., Wan, Y. L., Lin, G., Sequist, L. V., Fintelmann, F. J., & Barzilay, R. (2023). Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(12), 2191–2200. https://doi.org/10.1200/JCO.22.01345

18. Hamann, H. A., Ver Hoeve, E. S., Carter-Harris, L., Studts, J. L., & Ostroff, J. S. (2018). Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(8), 1062–1075. https://doi.org/10.1016/j.jtho.2018.05.014

19. National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England Journal of Medicine, 365(5), 395-409. https://doi.org/10.1056/NEJMoa1102873

20. Booz Allen Hamilton. (2021). AI tools for lung cancer detection. Booz Allen Hamilton Research. https://www.boozallen.com/

21. Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adarn, M. N., Bruhm, D. Velculescu, V. E. (2019). Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 570(7761), 385-389. https://doi.org/10.1038/s41586-019-1272-6

22. Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., Chiao, J. Y., Leal, A., Noe, M., White, J. R., Arun, A. S., Hruban, C., Annapragada, A. V., Jensen, S. Ø., Ørntoft, M. W., Madsen, A. H., … Velculescu, V. E. (2021). Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature communications, 12(1), 5060. https://doi.org/10.1038/s41467-021-24994-w

23. Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., ... & Lennon, A. M. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167-1177. https://doi.org/10.1016/j.annonc.2021.06.003

24. Peter J. Mazzone, Peter B. Bach, Jacob Carey, Caitlin A. Schonewolf, Katalin Bognar, Manmeet S. Ahluwalia, Marcia Cruz-Correa, David Gierada, Sonali Kotagiri, Kathryn Lloyd, Fabien Maldonado, Jesse D. Ortendahl, Lecia V. Sequist, Gerard A. Silvestri, Nichole Tanner, Jeffrey C. Thompson, Anil Vachani, Kwok-Kin Wong, Ali H. Zaidi, Joseph Catallini, Ariel Gershman, Keith Lumbard, Laurel K. Millberg, Jeff Nawrocki, Carter Portwood, Aakanksha Rangnekar, Carolina Campos Sheridan, Niti Trivedi, Tony Wu, Yuhua Zong, Lindsey Cotton, Allison Ryan, Christopher Cisar, Alessandro Leal, Nicholas Dracopoli, Robert B. Scharpf, Victor E. Velculescu, Luke R. G. Pike; Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection. Cancer Discov 2024; https://doi.org/10.1158/2159-8290.CD-24-0519

25. Lennon, A. M., Phallen, J., Adarn, M. N., & Velculescu, V. E. (2024). AI-based liquid biopsy for lung cancer detection: A new screening approach. Cancer Discovery, 14(6), 890-902. https://doi.org/10.1158/2159-8290.CD-24-0612

26. Schouten, H. J., & Schreiber, R. D. (2022). Liquid biopsies and the future of early cancer detection. Journal of Clinical Oncology, 40(2), 194-202. https://doi.org/10.1200/JCO.22.00111

27. National Cancer Institute. (2023). Advances in liquid biopsy technology for cancer detection. National Cancer Institute (NCI). https://www.cancer.gov/news-events

28. Zhou H, Watson M, Bernadt CT, Lin S, Lin CY, Ritter JH, Wein A, Mahler S, Rawal S, Govindan R, Yang C and Cote RJ. AI-guided histopathology predicts brain metastasis in lung cancer patients. The Journal of Pathology. March 4, 2024. DOI: 10.1002/path.6263

29. Duma N, Santana-Davila R, Molina JR. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings. 2019;94(8):1623-1640. doi:10.1016/j.mayocp.2019.01.013.

30. Johns Hopkins Kimmel Cancer Center, et al. (Year). Study on AI-based Liquid Biopsy Test

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1384-1397 | ISSN:2251-6727

for Early Lung Cancer Detection. Cancer Discovery.

31. Jin J, Hu Z, Kockx M, Wang J, Scharpf R, Pritchard TS, et al. Development and Validation of a Liquid Biopsy for Early Detection of Lung Cancer Through Analysis of Cell-Free DNA Fragment Patterns. Cancer Discovery. 2019;9(10):1306-1315. doi:10.1158/2159-8290.CD-19-0373.
32. Velculescu VE, Scharpf RB, Phallen J, Adleff V, O'Connell C, Kockx M, et al. Non-invasive early detection of cancer using circulating cell-free DNA fragmentomes. Nature. 2021;593(7857):564-569. doi:10.1038/s41586-021-03437-0.
33. Phallen J, Adleff V, O'Connell C, et al. Early Detection of Cancer Using DNA Fragment Patterns in Blood Samples: Results From a Multi-Center Prospective Study. Cancer Discovery. 2021;11(6):1462-1474. doi:10.1158/2159-8290.CD-21-0045.
34. Jin Z, Zhou Y, Sheng X, et al. The role of artificial intelligence in the prediction and diagnosis of lung cancer biomarkers. Journal of Thoracic Oncology. 2021;16(7):1104-1112. doi:10.1016/j.jtho.2021.02.019.
35. Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications. 2014;5:4006. doi:10.1038/ncomms5006.
36. Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications. 2014;5:4006. doi:10.1038/ncomms5006.
37. Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature Communications. 2014;5:4006. doi:10.1038/ncomms5006.
38. . Jiang Y, Liu Y, Lee PL, et al. Development and Validation of a Radiomic-Based Signature for Lung Cancer Risk Prediction: A Feasibility Study. Journal of the National Cancer Institute. 2020;112(5):467-474. doi:10.1093/jnci/djz181.
39. Zhu X, Dong D, Chen Z, et al. Multimodal Deep Learning Model for Predicting Lung Cancer Survival Time Based on CT and PET/CT Images. Frontiers in Oncology. 2021;11:665867. doi:10.3389/fonc.2021.665867.
40. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: The bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology. 2017;14(12):749-762. doi:10.1038/nrclinonc.2017.141.
41. Schilsky RL, Michels DL, Meropol NJ, et al. Building a National Cancer Knowledge Network. Journal of Clinical Oncology. 2014;32(32):3635-3640. doi:10.1200/JCO.2014.57.6669.
42. Ardila D, Kiraly AP, Bharadwaj S, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine. 2019;25(6):954-961. doi:10.1038/s41591-019-0447-x.
43. Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. Cancer Letters. 2020;471:61-71. doi:10.1016/j.canlet.2019.12.007.
44. Wang D, Khosla A, Gargeya R, Irshad H, Beck AH. Deep learning for identifying metastatic breast cancer. Nature Medicine. 2016;22(8):1000-1004. doi:10.1038/nm.4381.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 1384-1397 | ISSN:2251-6727

45. Kannan K, Wang L. Developing a comprehensive multi-omics platform for cancer precision medicine. Cancer Cell. 2020;37(4):443-446. doi:10.1016/j.ccell.2020.03.012.

46. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biology. 2017;18(1):83. doi:10.1186/s13059-017-1215-1.

47. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7.

48. Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular Cancer Therapeutics. 2017;16(11):2598-2608. doi:10.1158/1535-7163.MCT-17-0386.